These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
576 related articles for article (PubMed ID: 21993268)
1. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Bartosch C; Manuel Lopes J; Oliva E Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268 [TBL] [Abstract][Full Text] [Related]
2. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767 [TBL] [Abstract][Full Text] [Related]
4. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related]
5. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium. Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946 [TBL] [Abstract][Full Text] [Related]
6. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Lax SF; Kurman RJ Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874 [TBL] [Abstract][Full Text] [Related]
7. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726 [TBL] [Abstract][Full Text] [Related]
8. p16 expression in the female genital tract and its value in diagnosis. O'Neill CJ; McCluggage WG Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152 [TBL] [Abstract][Full Text] [Related]
9. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230 [TBL] [Abstract][Full Text] [Related]
10. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Quddus MR; Sung CJ; Zhang C; Lawrence WD Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071 [TBL] [Abstract][Full Text] [Related]
11. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909 [TBL] [Abstract][Full Text] [Related]